SEOUL, July 29 (Reuters) - South Korean pharmaceutical

company Celltrion said on Tuesday that in a bid to

offset the risk of U.S. tariffs it had become the preferred

bidder to acquire an unnamed pharmaceutical company with a U.S.

production facility.

Celltrion's CEO said it planned to invest 700 billion won

($503.78 million) in the factory.